Valuation : Algorae Pharmaceuticals Limited

Market Cap 20.28M 14.62M 12.58M 11.85M 10.79M 20.2M 1.39B 140M 54.26M 709M 54.9M 53.71M 2.25B P/E 2025
-10x
P/E 2026 -6.55x
Enterprise Value 16.34M 11.78M 10.14M 9.55M 8.7M 16.27M 1.12B 113M 43.73M 571M 44.24M 43.28M 1.81B EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
66.95%
Yield 2025 *
-
Yield 2026 -
1 day-10.00%
1 week-14.29%
Current month-10.00%
1 month-25.00%
3 months-18.18%
6 months-30.77%
Current year-35.71%
1 week 0.01
Extreme 0.009
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.007
0.02
3 years 0
Extreme 0.005
0.02
5 years 0
Extreme 0.003999
0.02
10 years 0
Extreme 0.003999
0.28
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 18/06/2023
Corporate Secretary - 30/06/2026
Corporate Secretary - 30/06/2026
Director TitleAgeSince
Chairman 52 04/01/2023
Director/Board Member - 09/03/2026
Director/Board Member 52 13/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
-10.00%-14.29%+12.50%-35.71% 14.62M
-0.94%-0.71%+45.60%+103.25% 68.52B
-0.95%-6.07%+30.68%+74.29% 62.88B
+3.13%+1.71%-12.50%+390.48% 28.13B
-2.74%-6.31%+26.33%+11.24% 25.56B
-0.54%-5.47%-3.88%-18.31% 24.65B
-1.97%-4.82%+18.20%-19.33% 19.81B
-4.27%+3.07%+211.22%+362.48% 17.69B
-1.37%-4.51%-5.21%+507.43% 14.66B
+1.14%-0.34%+52.38%+163.82% 14.45B
Average -1.86%-2.37%+37.53%+153.96% 27.64B
Weighted average by Cap. -0.86%-1.87%+36.39%+138.95%

Financials

2025 2026
Net sales - -
Net income -803K -579K -498K -469K -427K -800K -55.1M -5.56M -2.15M -28.07M -2.17M -2.13M -88.92M -2.71M -1.95M -1.68M -1.58M -1.44M -2.7M -186M -18.77M -7.25M -94.76M -7.34M -7.18M -300M
Net Debt -2.32M -1.67M -1.44M -1.36M -1.23M -2.31M -159M -16.06M -6.21M -81.07M -6.28M -6.14M -257M -3.94M -2.84M -2.44M -2.3M -2.1M -3.92M -270M -27.26M -10.54M -138M -10.66M -10.43M -436M
Logo Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled pharmaceutical development company. The Company’s proprietary AI platform, Algorae Operating System (AlgoraeOS), is an AI platform that leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. Its other drug candidates include AI-116, AI-168, NTCELL. AI-116 is a combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease. AI-168 is a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient, which is conceptualized to be a potential treatment for cardiovascular disease, including hypertension. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.
Employees
48
Date Price Change Volume
10/09/26 A$0.009000 -10.00% 50,214
09/09/26 A$0.0100 -9.09% 15,961
04/09/26 A$0.0110 +4.76% 3,075,587
03/09/26 A$0.0105 -4.55% 885,388
02/09/26 A$0.0110 +10.00% 11,035
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!